"Ryan Sperry, VP of integrated client solutions, Basis Technologies: The Trump administration and those close to it have made it clear they’re not fans of how prevalent pharma marketing is in the U.S. Some of the opinions from those like RFK Jr. even suggest getting rid of pharmaceutical advertising altogether, though that would clash with First Amendment protections. I expect the industry will see tighter regulations around how patient data is used in advertising, a trend already occurring with legislation like Washington’s My Health My Data Act, which other states are beginning to adopt."
Read more in MedAdNews.
“Definitely not too little, too late. It’s a lot of money,” said Jaime Vasil Winkelfoos, group vice president for Candidates ...
"As VP of Research and Insights at ANA member company Basis, Maggie Nemoy spends her days researching shifting trends in ...
Basis has made the shortlist for The Drum B2B World Fest Awards. Our 'Seamless' campaign is nominated in the category ...
